Diabetic Polyneuropathy in Type 2 Diabetes: Impact of Lipid Parameters and Glucose-lowering Therapy

Abstract

Type 2 diabetes mellitus (T2DM) affects approximately 9% of the global adult population and is associated with numerous complications. Diabetic polyneuropathy (DPN) is one of the most common complications and prevention is an essential part in T2DM management. However, prevention initiatives are limited because of an incomplete understanding of key modifiable risk factors. In this study, we aim to examine whether lipid parameters (triglycerides, LDL cholesterol, HDL cholesterol, and non-HDL cholesterol) are associated with DPN after adjustment for confounders and to identify the optimal lipid marker to monitor DPN risk in clinical practice. We also want to examine whether new newer glucose-lowering drug classes, sodium–glucose cotransporter 2 inhibitors and glucagon Like Peptide 1 receptor agonists, can prevent DPN.

Formål

1. To examine whether lipid parameters (triglycerides, LDL cholesterol, HDL cholesterol, and non-HDL cholesterol) are associated with DPN after adjustment for confounders.
2. To determine whether these lipid parameters carried any predictive value for DPN beyond elevated triglyceride levels.
3. To investigate the effect of SGLT2i or GLP-1RA on the risk of DN.

Studiepopulation

We will use two independent T2DM cohorts each with certain advantages:
1) a register based T2DM cohort representing everyday clinical practice, allowing long-term follow-up 
2) a clinically recruited T2DM cohort (i.e., the DD2 cohort) with detailed information on lifestyle and anthropometry measures at baseline.

Artikler

• Kristensen et al (2024). Lipid levels and risk of diabetic polyneuropathy in 2 Danish type 2 diabetes cohorts. Neurology.

Finansiering

The proposed project is part of an ongoing PhD project fully funded by a PhD grant from Aarhus University.